ArticleHypertension research : official journal of the Japanese Society of Hypertension2016
The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line.
Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Soluble neprilysin: A versatile biomarker for heart failure, cardiovascular diseases and diabetic complications-A systematic review.Indian heart journalPooled it
- Low-fat hypocaloric diet reduces neprilysin in overweight and obese human subjects.ESC heart failure · 2021Trial
- Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (Pro)renin receptor level.Hypertension research : official journal of the Japanese Society of Hypertension · 2018Trial
- Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.Cardiovascular therapeutics · 2016Trial
- Inhibitory mechanism of ANP on aldosterone production in human adrenocortical cells.Endocrine connections · 2026Article
- Screening and Diagnosis of Primary Aldosteronism in Patients Using Renin-Angiotensin System Inhibitors.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction: A Novel Framework to Explain Pathogenesis and Guide Treatment.Journal of the American College of Cardiology · 2025Review
- Renin-angiotensin-aldosterone system and its relation to hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Review
- Addition of Sacubitril/Valsartan to Mineralocorticoid Receptor Antagonist Therapy in Primary Aldosteronism: Effects on Plasma Aldosterone Concentration and Plasma Renin Activity.Journal of clinical medicine research · 2024Article
- Unveiling Wide Spectrum Therapeutic Implications and Signaling Mechanisms of Valsartan in Diverse Disorders: A Comprehensive Review.Current drug research reviews · 2024Review
- The renin-angiotensin-aldosterone system: a new look at an old system.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- Aldosterone breakthrough from a pharmacological perspective.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Review
- Effects of Sacubitril/Valsartan on the Expression of CaMKII/CaBioMed research international · 2022Article
- Angiotensin Receptor Blocker and Neprilysin Inhibitor Suppresses Cardiac Dysfunction by Accelerating Myocardial Angiogenesis in Apolipoprotein E-Knockout Mice Fed a High-Fat Diet.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2021Article
- Impact of mineralocorticoid receptor blockade with direct renin inhibition in angiotensin II-dependent hypertensive mice.Hypertension research : official journal of the Japanese Society of Hypertension · 2020Article
- Diagnosis and treatment of heart failure with preserved left ventricular ejection fraction.World journal of cardiology · 2020Review
- Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2018Article
- Dual inhibitory action on aldosterone by combined angiotensin receptor antagonism and neprilysin inhibition.Hypertension research : official journal of the Japanese Society of Hypertension · 2016Article
- The place of ARBs in heart failure therapy: is aldosterone suppression the key?Therapeutic advances in cardiovascular diseaseReview
Corrections and comments
- Commented on by
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A recent clinical study indicated that an angiotensin II (Ang II) type 1 (AT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.